1. Bruton OC. Agammaglobulinemia. Pediatrics 1952;9(6):722–8. 2. Shehata N, Palda V, Bowen T, et al. The Use of Immunoglobulin Therapy for Patients With Primary Immune Deficiency: An Evidence-Based Practice Guideline. Transfus Med Rev 2010;24(SUPPL. 1). 3. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease:A review of evidence. J Allergy Clin Immunol 2017;139(3):S1–46. 4. Ballow M. Mechanisms of immune regulation by IVIG. Curr. Opin. Allergy Clin. Immunol. 2014;14(6):509–15. 5. ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-Deaminase Deficinecy in Two Patients With Severely Impaired Cellular Immunity. Lancet 1972;300(7786):1067–9. 6. Zegers BJM, Stoop JW. Metabolic Causes of Immune Deficiency: Mechanisms and Treatment. In: Immunodeficiency and Disease. 1988. p. 113–31. 7. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine Deaminase. N Engl J Med 1987;316(10):589–96. 8. Hershfield MS. PEG‐ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum. Mutat. 1995;5(2):107–12. 9. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood 2009;114:3524–32. 10. Gaspar HB, Cooray S, Gilmour KC, et al. Immunodeficiency: Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011;3(97). 11. Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: Development trends and strategies. J Pharm Bioallied Sci 2010;2(4):290. 12. Chambers CA, Krummel ME, Boitel B, et al. The Role of CTLA-4 in the Regulation and Initiation of T-Cell Responses. Immunol Rev 1996;153(1):27–46. 13. Lo B, Zhang K, Lu W, et al. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 2015;349(6246):436–40. 14. Schubert D, Bode C, Kenefeck R, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 2014;20(12):1410–6. 15. Kuehn O. Immune Dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 2014;4:6–11. 16. Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency. Blood 2016;128(8):1037–42. 17. Alangari A, Alsultan A, Adly N, et al. LPSresponsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. J Allergy Clin Immunol 2012;130(2):481–8. 18. Lopez-Herrera G, Tampella G, PanHammarström Q, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. Am J Hum Genet 2012;90:986–1001. 19. Kiykim A, Ogulur I, Dursun E, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract 2019; 20. Schwab C, Gabrysch A, Olbrich P, et al.Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. J Allergy Clin Immunol 2018;142(6):1932–46. 21. Baehner RL, Nathan DG. Leukocyte oxidase: Defective activity in chronic granulomatous disease. Science 1967;155(3764):835–6. 22. Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest 1967;46(4):668–79. 23. Holland SM. Chronic Granulomatous Disease. Hematol Oncol Clin North Am 2013;27(1):89–99. 24. Thomsen IP, Smith MA, Holland SM, Creech CB. A Comprehensive Approach to the Management of Children and Adults with Chronic Granulomatous Disease. J Allergy Clin Immunol Pract 2016;4(6):1082–8. 25. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease. N Engl J Med 2010;363(27):2600–10. 26. Marciano BE, Spalding C, Fitzgerald A, et al. Common Severe Infections in Chronic Granulomatous Disease. Clin Infect Dis 2015;60(8):1176–83. 27. Slack MA, Thomsen IP. Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease. J Pediatric Infect Dis Soc 2018;7(suppl1):S25-S30. 28. Ezekowitz RA, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in Xlinked variant chronic granulomatous disease. J Clin Invest 1987;80(4):1009–16. 29. International Chronic Granulomatous Disease Cooperative Study Group. A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease. N Engl J Med 1991;324(8):509–16. 30. Marciano BE, Wesley R, De Carlo ES, et al. Long-Term Interferon-Therapy for Patients with Chronic Granulomatous Disease. Clin Infect Dis 2004;39(5):692–9. 31. Jackson SH, Miller GF, Segal BH, et al. IFN- $γ$ Is Effective in Reducing Infections in theMouse Model of Chronic Granulomatous Disease (CGD). J Interf &Cytokine Res 2001;21(8):567–73. 32. Naderi beni F, Fattahi F, Mirshafiey A, et al. Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. Int Immunopharmacol 2012;12(4):689–93. 33. Bustamante J, Boisson-Dupuis S, Abel L, Casanova J-L. Mendelian susceptibility to mycobacterial disease: Genetic, immunological, and clinical features of inborn errors of IFN-γ immunity. Semin Immunol 2014;26(6):454–70. 34. Rosain J, Kong X, Martinez‐Barricarte R, et al. Mendelian susceptibility to mycobacterial disease: 2014–2018 update. Immunol & Cell Biol 2019;97(4):360–7. 35. Kotenko S V., Izotova LS, Pollack BP, et al. Interaction between the Components of the Interferon γ Receptor Complex. J Biol Chem 1995;270(36):20915–21.36. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest 1997;100(11):2658–64. 37. Remiszewski P, Roszkowska-Śliz B, Winek J, et al. Disseminated Mycobacterium avium Infection in a 20-Year-Old Female with Partial Recessive IFNγR1 Deficiency. Respiration 2006;73(3):375–8. 38. Ward CM, Jyonouchi H, Kotenko S V, et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur J Pediatr 2007;166(9):981–5. 39. Liu S-Y, Sanchez DJ, Aliyari R, Lu S, Cheng G. Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci 2012;109(11):4239–44. 40. Bax HI, Freeman AF, Ding L, et al. Interferon Alpha Treatment of Patients with Impaired Interferon Gamma Signaling. J Clin Immunol 2013;33(5):991–1001. 41. Bouchonnet F, Boechat N, Bonay M, Hance AJ. Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun 2002;70(6):3020–5. 42. Nguyen KB, Cousens LP, Doughty LA, Pien GC, Durbin JE, Biron CA. Interferon α/βmediated inhibition and promotion of interferon γ: STAT1 resolves a paradox. Nat Immunol 2000;1(1):70–6. 43. de Wetering D van, van Wengen A, Savage NDL, van de Vosse E, van Dissel JT. IFN-α cannot substitute lack of IFN-γ responsiveness in cells of an IFN-γR1 deficient patient. Clin Immunol 2011;138(3):282–90. 44. Alangari AA, Al-Zamil F, Al-Mazrou A, et al. Treatment of disseminated mycobacterial infection with high-dose IFN-γ in a patient with IL-12Rβ1 deficiency. Clin Dev Immunol 2011;2011:691956. 45. Prando C, Samarina A, Bustamante J, et al. Inherited IL-12p40 Deficiency. Medicine (Baltimore) 2013;92(2):109–22. 46. Villarino A V., Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 2017;18(4):374–84. 47. Reich NC. STAT dynamics. Cytokine & growth factor Rev 2007;18(5–6):511–8. 48. Najjar I, Fagard R. STAT1 and pathogens, not a friendly relationship. Biochimie 2010;92(5):425–44. 49. Liu L, Okada S, Kong X-F, et al. Gain-offunction human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011;208(8):1635–48. 50. Toubiana J, Okada S, Hiller J, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 2016;127(25):3154–64. 51. Depner M, Fuchs S, Raabe J, et al. The Extended Clinical Phenotype of 26 Patients withChronic Mucocutaneous Candidiasis due to Gainof Function Mutations in STAT1. J Clin Immunol 2016;36(1):73–84. 52. Uzel G, Sampaio EP, Lawrence MG, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation– polyendocrinopathy–enteropathy–X-linked–like syndrome. J Allergy Clin Immunol 2013;131(6):1611--1623.e3. 53. Baris S, Alroqi F, Kiykim A, et al. Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1. J Clin Immunol 2016;36(7):641–8. 54. Tabellini G, Vairo D, Scomodon O, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol 2017;140(2):553--564.e4. 55. Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol 2018;142(5):1665–9. 56. Meesilpavikkai K, Dik WA, Schrijver B, et al. Baricitinib treatment in a patient with a gain-offunction mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol 2018;142(1):328--330.e2. 57. Vargas-Hernández A, Mace EM, Zimmerman O, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol 2018;141(6):2142--2155.e5. 58. Weinacht KG, Charbonnier L-M, Alroqi F, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 2017;139(5):1629-1640.e2. 59. Harris TJ, Grosso JF, Yen H-R, et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007;179(7):4313–7. 60. Chandrasekaran P, Zimmerman O, Paulson M, et al. Distinct mutations at the same positions of STAT3 cause either loss or gain of function. J Allergy Clin Immunol 2016;138(4):1222-- 1224.e2. 61. Milner JD, Vogel TP, Forbes L, et al. Earlyonset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015;125(4):591–9. 62. Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009;30(12):592–602. 63. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. Nat Genet 2014;46(8):812–4. 64. Haddad E. STAT3: too much may be worse than not enough! 2015; 65. Haapaniemi EM, Kaustio M, Rajala HLM, et al. Autoimmunity, hypogammaglobulinemia,lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood 2015;125(4):639–48. 66. Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in Human Disease. J Clin Immunol 2015;35(7):615–23. 67. Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nat Publ Gr 2016;16(11):702–14. 68. Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 2013;342(6160):866–71. 69. Deau M-C, Heurtier L, Frange P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest 2014;124(9):3923–8. 70. Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol 2016;183(2):221–9. 71. Lucas CL, Kuehn HS, Zhao F, et al. Dominantactivating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15(1):88– 97. 72.Maccari ME, Abolhassani H, Aghamohammadi A, et al. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for ImmunodeficienciesActivated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol 2018;9:543. 73. Rao VK, Webster S, Dalm VASH, et al. Effective activated PI3Kδ syndrome-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood 2017;130(21):2307–16. 74. Wetzler M, Talpaz M, Kleinerman ES, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 1990;89(5):663–72. 75. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002;16(10):1992–2003. 76. Suratt BT, Petty JM, Young SK, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 2004;104(2):565– 71. 77. Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003;34(1):70–4. 78. Kawai T, Choi U, Whiting-Theobald NL, et al. Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol 2005;33(4):460–8. 79. Gulino A.V, Moratto D, Sozzani S, et al.Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 2004;104(2):444–52. 80. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and nonHodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45(1):39–47. 81. McDermott DH, Lopez J, Deng F, et al. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med 2011;15(10):2071–81. 82. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011;118(18):4957–62. 83. McDermott DH, Pastrana D V, Calvo KR, et al. Plerixafor for the Treatment of WHIM Syndrome. N Engl J Med 2019;380(2):163–70. 84. Zhou Q, Yang D, Ombrello AK, et al. Earlyonset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014;370(10):911–20. 85. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): Updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 2018;38(5):569–78. 86. Zavialov A.V., Engström Å. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J 2005;391(1):51–7. 87. Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: A multicentre national study. Ann Rheum Dis 2017;76(10):1648–56. 88. Ombrello AK, Bethesda, Qin J, et al. Treatment strategies for deficiency of adenosine deaminase 2. N. Engl. J. Med. 2019;380(16):1582–4. 89. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29(3):301–5. 90. Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat. Immunol. 2017;18(8):832–42. 91. Aksentijevich I, Putnam CD, Remmers EF, et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56(4):1273–85. 92. Mortimer L, Moreau F, MacDonald JA, Chadee K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat Immunol 2016;17(10):1176–86. 93. Jesus AA, Goldbach-Mansky R. IL-1 Blockade in Autoinflammatory Syndromes. Annu Rev Med 2014;65(1):223–44. 94. Hoffman HM, Throne ML, Amar NJ, et alEfficacy and safety of rilonacept (Interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58(8):2443–52. 95. Lachmann HJ, Kone-Paut I, KuemmerleDeschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360(23):2416–25. 96. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006;355(6):581–92. 97. Harris ES, Weyrich AS, Zimmerman GA. Lessons from rare maladies: Leukocyte adhesion deficiency syndromes. Curr Opin Hematol 2013;20(1):16–25. 98. Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 2000 2015;69(1):142– 59. 99. Moutsopoulos NM, Zerbe CS, Wild T, et al. Interleukin-12 and interleukin-23 blockade in leukocyte adhesion deficiency type 1. N Engl J Med 2017;376(12):1141–6.